...And there ya go.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
...And there ya go.
WELCOME TO THE ROARING TWENTIES!!!!
WHATEVER HAPPENED TO THAT
WHATEVER HAPPENED TO THAT
Berkeley Lights, Inc. (BLI) AT THAT HAPPY PRICE!
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
$45.04-1.42 (-3.05%)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
$45.04-1.42 (-3.05%)
THIS jnce is tempting
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital 13:58 JNCE, GILD Roth Capital analyst Zegbeh Jallah notes that Jounce Therapeutics (JNCE) announced IND-clearance for JTX-1811, its CCR8 antibody licensed to Gilead (GILD), and per the agreement, this milestone triggers a $25M payment to Jounce. Gilead will now also assume all future development associated with the program, and Jounce is eligible to receive an additional $660M in milestone payments plus royalties. The analyst believes that JTX-1811 has significant potential in immuno-oncology, further validating Jounce's immunooncology platform, and looks forward to hearing more at the company's Virtual R&D day on June 23rd. Jallah has a Buy rating and a price target of $15 on Jounce's shares. Show Related Items >>
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital 13:58 JNCE, GILD Roth Capital analyst Zegbeh Jallah notes that Jounce Therapeutics (JNCE) announced IND-clearance for JTX-1811, its CCR8 antibody licensed to Gilead (GILD), and per the agreement, this milestone triggers a $25M payment to Jounce. Gilead will now also assume all future development associated with the program, and Jounce is eligible to receive an additional $660M in milestone payments plus royalties. The analyst believes that JTX-1811 has significant potential in immuno-oncology, further validating Jounce's immunooncology platform, and looks forward to hearing more at the company's Virtual R&D day on June 23rd. Jallah has a Buy rating and a price target of $15 on Jounce's shares. Show Related Items >>
Jaguar Land Rover working on hydrogen fuel cell electric vehicle, Verge reports 14:20 TTM Jaguar Land Rover, a subsidiary of Tata Motors, is developing a prototype hydrogen fuel cell electric vehicle, which it intends to begin testing later this year, The Verge's Kim Lyons reports. The car maker said the vehicle is based on its Land Rover Defender, and the company will focus its testing on "key attributes," including fuel consumption and off-road capabilities, Lyons says
Butterfly Network call volume above normal and directionally bullish 13:25 BFLY
What is the real story here?
Hundreds of Southwest flights canceled for a third day, NY Times reports 13:12 LUV Southwest delayed or canceled hundreds of flights on Wednesday, the third straight day, as the company sought to resolve disruptions, The New York Times' Niraj Chokshi and Coral Murphy Marcos reports. According to FlightAware, about 8% of the airline's flights had been canceled and another 14% had been delayed as of midday Wednesday. Reference Link
Hundreds of Southwest flights canceled for a third day, NY Times reports 13:12 LUV Southwest delayed or canceled hundreds of flights on Wednesday, the third straight day, as the company sought to resolve disruptions, The New York Times' Niraj Chokshi and Coral Murphy Marcos reports. According to FlightAware, about 8% of the airline's flights had been canceled and another 14% had been delayed as of midday Wednesday. Reference Link
Hey good job.im in MQ at 29.7
Maybe see if you can sell a few July $30 covered calls on it. I bet you can get $2.75
That'll protect your downside and I think $32 will be a near term cap on it.
Should be safe thru July expiration.